Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Drug development

Topic: Drug trials: efficacy and safety

Plain-language summary

Buse, MD PhDDiabetes Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina (J.B.B.), and the LEADER Publication Committee on behalf of the LEADER Trial Investigators*Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1569 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Comorbidities and complications associated with type 2 diabetes mellitus (T2DM) increase with age, making treatment of elderly persons with this condition challenging. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byNewer Glucose-Lowering Therapies in Older Adults with Type 2 DiabetesComparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient CharacteristicsHypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotypeLe risque de dénutrition chez le sujet âgé diabétique : une limite à l'utilisation des « nouvelles » classes thérapeutiques ?Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology—Cardiovascular Round TableCardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonistsCardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanismsOptimal Type 2 Diabetes Mellitus Management and Active AgeingLow glycaemic state increases risk of frailty and functional decline in older people with type 2 diabetes mellitus – Evidence from a systematic reviewDipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysisType 2 diabetes mellitus in older adults: clinical considerations and managementApproach to Obesity in the Older PopulationNewer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older peopleDirection for Basal Insulin Therapy by Once Daily Injection in the Clinical PracticeEfficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trialGLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysisCardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with t

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gilbert, M. P., Bain, S. C., Franek, E., Jódar-Gimeno, E., Nauck, M. A., Pratley, R. E., et al. (2018). Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/m18-1569

Vancouver

Gilbert MP, Bain SC, Franek E, Jódar-Gimeno E, Nauck MA, Pratley RE, et al. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Annals of Internal Medicine. 2018. doi:10.7326/m18-1569. PMID: 30508430.

BibTeX

@article{gilbert2018-30508430,
  author  = {Gilbert, Matthew Philip and Bain, Stephen Charles and Franek, Edward and Jódar-Gimeno, Esteban and Nauck, Michael Albrecht and Pratley, Richard E. and Rea, Rosangela Roginski and Saraiva, José Francisco Kerr and others},
  title   = {{Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial}},
  journal = {Annals of Internal Medicine},
  year    = {2018},
  doi     = {10.7326/m18-1569},
  pmid    = {30508430},
  url     = {https://doi.org/10.7326/m18-1569}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 69/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 1 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read 0 of 2. 40 of the 58 points it could be judged on, which is 69 of 100. Total 69 of 100.40 of the 58 points we could judge = 69 of 100

Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 40 of the 58 points we could judge it on, which is 69 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Annals of Internal Medicine)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 11 / 12 A randomized controlled trial
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30508430)
Free to read 0 / 2 Behind a paywall — scores zero
Points 40 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 40 of the 58 points we could judge it on is 69 out of 100.
Total 69 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Drug development from nearby years

Also in Drug development

124 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →